Sensus Healthcare, Inc. (SRTS) Stock Score, Valuation & Financial Research
Sensus Healthcare, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for SRTS
Sensus Healthcare, Inc. currently has a Wall Street Score of 29/100. The stored market price is $3.13. Its financial score is 32/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sensus Healthcare, Inc. does
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuratio
SRTS financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $3.13
- Market capitalization:
- $51.5M
- Revenue:
- $22.5M
- Net income:
- $-7.8M
- Free cash flow:
- $332K
- Cash:
- $18.3M
- Total debt:
- $407K
- EPS:
- -0.47
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 10/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $332K, showing positive cash generation.
- The balance sheet shows $18.3M of cash versus $407K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SRTS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.